溃疡对肢端黑色素瘤预后价值的差异:基于Breslow厚度与临床分期的回顾性研究
这项多中心回顾性研究纳入2000年1月至2017年12月诊断的1053例肢端黑色素瘤患者,评估溃疡对黑色素瘤特异性生存(MSS)的影响。中位随访61个月,溃疡组中位MSS为66.1个月(95%CI 60.0-86.0),无溃疡组未达到,HR 1.41(95%CI 1.09-1.82,P=0.012)。溃疡是独立负性预后因素,但仅在薄(≤1 mm)黑色素瘤中显著影响预后,在厚度>1 mm或III期患者中无显著关联。
要点
- 溃疡是肢端黑色素瘤独立负性预后因素,HR 1.41(95%CI 1.09-1.82,P=0.012)。
- 薄(≤1 mm)黑色素瘤中,溃疡组与无溃疡组生存曲线明显分离(P<0.001)。
- 厚度>1 mm(T2、T3、T4亚组)或III期患者中,溃疡与MSS无显著关联。
核心结论
- 溃疡是肢端黑色素瘤患者的独立负性预后因素,但其影响随Breslow厚度和临床分期而异。
- 溃疡对薄(≤1 mm)黑色素瘤预后有显著影响,但在中/厚肢端黑色素瘤或III期患者中溃疡与生存无关联。
研究设计与样本
- 多中心回顾性研究,纳入2000年1月至2017年12月诊断的肢端黑色素瘤患者1053例。
- 采用多变量Cox比例风险模型和log-rank检验比较溃疡组与无溃疡组的黑色素瘤特异性生存差异。
主要发现
- 1053例患者中62.6%存在溃疡。
- 中位随访61个月,溃疡组中位MSS为66.1个月(95%CI 60.0-86.0),无溃疡组未达到,HR 1.41(95%CI 1.09-1.82,P=0.012)。
- 薄(≤1 mm)黑色素瘤中,溃疡组与无溃疡组生存曲线随时间明显分离(P<0.001)。
- 厚度>1 mm(T2、T3、T4亚组)患者中,溃疡与MSS无显著关联(所有P值>0.05)。
- III期患者中,溃疡与MSS无显著关联(HR 1.09,95%CI 0.71-1.68,P=0.39)。
关键数值与推荐
- 溃疡组中位MSS 66.1个月(95%CI 60.0-86.0) vs 无溃疡组未达到,HR 1.41(95%CI 1.09-1.82,P=0.012)。
- III期患者中溃疡与MSS的HR 1.09(95%CI 0.71-1.68,P=0.39)。
- 薄(≤1 mm)黑色素瘤中溃疡组与无溃疡组生存曲线分离P<0.001。
临床怎么用
- 作者认为,使用基于溃疡的分期系统时应考虑上述 findings。
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ulceration is regarded as an adverse prognostic factor and is used together with tumour thickness to subcategorize patients with cutaneous melanoma. However, the prognostic impact of ulceration in acral melanoma (AM) is controversial. OBJECTIVES: To assess the prognostic impact of ulceration in AM and the variability across different Breslow thicknesses and clinical stages. METHODS: A multicentre retrospective study of patients diagnosed with AM between January 2000 and December 2017. Differences in melanoma-specific survival (MSS) between patients with and without ulceration were assessed using the multivariable Cox proportional hazards model and log-rank test. RESULTS: Among 1053 enrolled patients, 62.6% had ulceration. After a median follow-up of 61 months, patients with ulceration had a lower median MSS than those without: 66.1 months, 95% confidence interval (CI) 60.0-86.0 vs. not reached; hazard ratio 1.41, 95% CI 1.09-1.82; P = 0.012. Among patients with thin (≤ 1 mm) melanoma, the survival curves of patients with vs. without ulceration clearly separated over time (P < 0.001). No association between ulceration and MSS was observed for melanomas of thickness > 1 mm (subgroups of T2, T3 and T4; all P-values > 0.05) or patients with stage III disease (hazard ratio 1.09, 95% CI 0.71-1.68, P = 0.39). CONCLUSIONS: Ulceration is an independent negative prognostic factor for patients with AM, but the impact varies across Breslow thicknesses and clinical stages. Ulceration has a significant effect on prognosis for patients with thin (≤ 1 mm) melanoma, but there was no association between ulceration and survival in intermediate/thick AM or stage III AM. What is already known about this topic? Ulceration status is used together with Breslow tumour thickness to subcategorize patients into different stages according to the America Joint Committee on Cancer melanoma staging system. As one distinctive subtype of cutaneous melanoma, acral melanoma (AM) is characterized by poor survival outcomes due to delayed diagnosis and a high prevalence of negative prognostic and genetic features. The prognostic impact of ulceration in AM is still controversial. What does this study add? This was the first large-scale study to assess the prognostic and staging values of ulceration in patients with AM. Ulceration has a significant effect on prognosis for patients with thin (≤1 mm) melanoma, but no association between ulceration and survival was found in intermediate/thick or stage III AM. These findings should be considered when using ulceration-based staging systems.
引用
- Wei X, Wu D, Chen Y, et al. Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study. Br J Dermatol. 2022. PMID: 35042273. doi:10.1111/bjd.21026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。